Mars Report
Growth, long/short equity, infrastructure, biotech

Introducing The New And Improved Implant Sciences

For Implant Sciences (OTCQB:IMSC), 2013 has proven to be the year where significant approvals, sales and achievements have led to a path of accelerated growth the company has been seeking for years. Put in words by the company's CEO Glenn Bolduc on the last conference call to investors, he reiterates that Implant Sciences a year ago and Implant Sciences today are two differentiated companies. Taking a closer look, we will examine what warrants the CEO to make these claims and review looming catalysts in the near term that could be a potential boon to the company and corresponding stock price.

Sales Penetrate All Time Highs: The Best Year in the Company's History

With revenues exceeding $12 million (...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details